EcoDrugPlus

C-C Chemokine Receptor Type 1

Ensembl ID : ENSNGAG00000016242
Gene Symbol: LOC103733149
2 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSNGAG00000015226
Gene Symbol: CCR2
3 Cross references
286 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSNGAG00000016708
Gene Symbol: CCR4
2 Cross references
253 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSNGAG00000015317
Gene Symbol: CCR5
3 Cross references
298 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSNGAG00000000658
Gene Symbol: CCR9
3 Cross references
262 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSNGAG00000012834
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSNGAG00000010277
Gene Symbol: DNMT1
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSNGAG00000005199
Gene Symbol: TOP1
3 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSNGAG00000009092
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSNGAG00000022516
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

E3 Ubiquitin-Protein Ligase Trim31-Like

Ensembl ID : ENSNGAG00000000543
Gene Symbol: LOC103729796
2 Cross references
290 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSNGAG00000015899
Gene Symbol: EML4
3 Cross references
209 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).